Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
A phase 3 trial of Flutamide, Bicalutamide, Goserelin / leuprolide, Buserelin and Triptorelin in Prostate cancer, run by Radiation Therapy Oncology Group, with a status the registry has not verified recently.
Overview
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer is a phase 3 interventional study registered as NCT00567580 by Radiation Therapy Oncology Group, with 1792 participants planned, started 2008-02 and due to reach its primary completion in 2018-07-12. Interventions recorded: PBRT, PLNRT, AA, LHRH agonist. Conditions recorded: Prostate Cancer.
Linked to the drug Buserelin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialRadiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Shares Buserelin, Flutamide, Triptorelin, Bicalutamide and the tag pipeline.
- TrialHormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
Shares Buserelin, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
- TrialHormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
Shares Buserelin, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
- TrialTwo Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Shares Buserelin, Flutamide, Triptorelin, Bicalutamide and the tag pipeline.
- TrialTriptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
Shares Flutamide, Triptorelin, Prostate cancer and the tag pipeline.
- TrialFlutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
Shares Flutamide, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
- TrialStandard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Shares Flutamide, Triptorelin, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
- TrialHormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
Shares Flutamide, Bicalutamide, Prostate cancer and the tag pipeline.